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Introduction
The quantitative methods based on dispropor-
tionality analysis (DA) [the relative reporting 
ratio (RRR), proportional reporting ratio (PRR) 
and reporting odds ratio (ROR)] are widely used 
in signal detection. In particular, the lower bound 
of the confidence intervals of these measures of 
disproportionality is popular in signal detection 
activities as it makes a signal of disproportionate 
reporting (SDR) less likely when the statistics are 
based on a small number of reports – that is, it is 
one approach to mitigate the false-positive bur-
den in DA.1–3 Recent studies have highlighted 
the importance of the database for the perfor-
mance of the methods used to perform the signal 
detection.4
The masking (or cloaking or competition bias 
effect) of the quantitative methods of signal detec-
tion is a collateral effect of the data-mining algo-
rithms which are based on DA, which was first 
described by Evans in his seminal study published 
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Background: The lower bound of the 95% confidence interval of measures of 
disproportionality (Lower95CI) is widely used in signal detection. Masking is a statistical 
issue by which true signals of disproportionate reporting are hidden by the presence of other 
medicines. The primary objective of our study is to develop and validate a mathematical 
framework for assessing the masking effect of Lower95CI.
Methods: We have developed our new algorithm based on the masking ratio (MR) developed 
for the measures of disproportionality. A MR for the Lower95CI (MRCI) is proposed. A 
simulation study to validate this algorithm was also conducted.
Results: We have established the existence of a very close mathematical relation between 
MR and MRCI. For a given drug–event pair, the same product will be responsible for the 
highest masking effect with the measure of disproportionality and its Lower95CI. The extent 
of masking is likely to be very similar across the two methods. An important proportion of 
identical drug–event associations affected by the presence of an important masking effect 
is revealed by the unmasking exercise, whether the proportional reporting ratio (PRR) or its 
confidence interval are used.
Conclusion: The detection of the masking effect of Lower95CI can be automated. The real 
benefits of this unmasking in terms of new true-positive signals (rate of true-positive/false-
positive) or time gained by the revealing of signals using this method have not been fully 
assessed. These benefits should be demonstrated in the context of prospective studies.
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in 2001.5–13 The masking is an effect by which an 
SDR5,14 for a given drug–event pair identified by 
quantitative methods might be suppressed because 
of the presence of another product in the same 
spontaneous reporting system database character-
ized by disproportionate reporting for the event of 
interest. To our knowledge, only two studies have 
estimated the extent and magnitude of the masking 
associated with the use of a disproportionality 
measure on two spontaneous reporting system 
databases, both using a mathematical algorithm.7,8
The public health impact of the masking is cur-
rently unknown, but some studies conducted on 
large databases have shown that rarely reported 
events, often of public health importance, were 
mostly affected by the masking.7 In addition, an 
increasing number of studies tend to show that 
removing masking products can reveal signals of 
potential public health importance.7,8,10 For that 
reason, recent PROTECT-IMI good signal 
detection practices have recommended the use of 
an unmasking algorithm if the masking effect is a 
concern or is substantial.4 IMI-PROTECT was a 
multinational research consortium composed of 
experts from academia, industry and health care. 
Its goal was the development of innovative tools 
to enhance the early detection and assessment of 
adverse drug reactions (ADRs). Its recommenda-
tions concerning masking were not prescriptive, 
being more of the nature of points for organiza-
tions to consider if contemplating implementa-
tion of masking/unmasking exercises on a global 
level or at the level of individual drug–event pairs.
The masking effect was originally associated with 
the (point pseudo-estimates of the) measures of 
disproportionality based on DA, such as the RRR, 
PRR and ROR, but not with their confidence 
intervals.6,15 Recent attempts have been made to 
develop an algorithm for the identification and 
quantification of the masking effect associated 
with the use of confidence intervals of measures 
of disproportionality.11 These empirical studies 
have suggested the existence of a link between the 
masking effects associated with the measures of 
disproportionality and their respective confidence 
interval without producing any formal algorithm 
to quantify this effect in spontaneous system 
reporting databases. The recent approaches used 
to assess the impact and effect of masking associ-
ated with the use of the lower bound of the 95% 
confidence interval (Lower95CI) of the ROR on 
spontaneous reporting system databases mostly 
rely on empirical knowledge.12
We have recently proposed an algorithm aimed at 
identifying the direction and magnitude of the 
masking effect associated with these measures.9 
This algorithm is based on the use of a simple intu-
itive metric called the masking ratio (MR). The 
MR provides a direct way to assess the direction 
(there is a masking effect if MR > 1, a revealing 
effect if MR < 1) and the magnitude of the mask-
ing effect (the value of the disproportionality will 
be multiplied by the value of the MR if the mask-
ing product for which it has been computed is 
removed from the analysis). However, there is cur-
rently no equivalent algorithm for the lower bound 
of the 95% confidence interval (Lower95CI).
We have developed a new mathematical algo-
rithm based on the framework developed for the 
measures of disproportionality – the MR, which 
has been extended to the masking associated 
with the Lower95CI. We are proposing a varia-
ble called the MR for the lower bound of the 
95% confidence interval (MRCI). This variable 
can be computed for all measures of dispropor-
tionality (Lower95CI for either RRR, PRR or 
ROR). We have explored the relation between 
the masking mechanisms associated with the 
measures of disproportionality and their respec-
tive confidence intervals. We discuss the conse-
quences of this relation as well as the practical 
computational aspects associated with the 
implementation of this algorithm.
Materials and methods
Considering a product (A) for which a DA is 
conducted, and a given masking product (B) and 
an event (E) of interest, we have previously 
defined the MR is defined as the ratio of the 
measures of disproportionality for product A, 
before (RRRA, PRRA or RORA) and after 
(RRRA(withoutB), PRRA(withoutB) or RORA(withoutB)) 







We have used the same rationale to devise a ratio 
that returns the exact value of the masking associ-
ated with a masking product B when the lower 
bound of the 95% confidence interval is used as a 
quantitative measure of signal detection to com-
pute SDRs for product A. The MRCI is a confi-
dence interval-based disproportionality metric 
calculated from a revised contingency table that 
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isolates the masking product (Table 1). We sim-
ply divide the value of the lower bound of the 
95% confidence interval before and after the 
removal of masking product B (Table 1) to obtain 
the exact value of the MR associated with the use 
of the confidence interval. We therefore define 
the MRCI for the Lower95CI for any of the 









A masking effect is present when MRCI is >1. 
The direction and magnitude of the masking is 
given directly by the value of MRCI. The compu-
tation can be performed at the drug–event level 
(Table 1) or at the report level (Table 2).5,9 We 
have tested and validated our algorithm using a 
simulation of over 2,000,000 contingency tables 
and applied the different scenarios of allocation of 
the reports containing both the product of inter-
est (A) and the masking product (B). The range 
of values selected for the different cells of the con-
tingency table and the percentage of reports in 
common between the product of interest, prod-
uct A, and the masking product, B, are displayed 
in Table 3. The number of simulated reports sup-
posed to contain both products A and B were 
allocated to product A. We have used the PRR for 
our analyses of disproportionality.8,9,16 The exact 
MR for the PRR was used to perform all the com-
putations of the MR for the lower confidence 
limit (Table 4). For each combination of the sim-
ulated values, we have calculated the initial PRR 
for the product A (PRRA) and the unmasked 
PRRA(WithoutProductB) (after removal of the masking 
product B), the confidence interval for the PRR 
before (Lower95CI PRRA) and after (Lower95CI 
PRRA[after]) the removal of the masking product 
as well as the corresponding MRs (MR for the 
PRRA), observed MRCI (Equation 1) and calcu-
lated MRCI (Equation 3).
Table 1. Contingency table for the computation (at the drug–event level) of measures of disproportionality in 
the presence of a masking medicinal product. It includes two products: one for which the disproportionality 
analysis is performed (A) and a masking product (B). The nij correspond to the number of records involving the 
drug–event combinations present in the database.
Event (E) of interest Other events Total
Records containing Product A n11 n12 n1.
Records containing product B (masking) n21 n22 n2.
All other products in the database 
(excluding both A and B)
n31 n32 n3.
Total n.1 n.2 n..
Table 2. Contingency table for the computation (at the report level) of measures of disproportionality in the 
presence of a masking medicinal product. It includes two products: one for which the disproportionality 
analysis is performed (A) and a masking product (B). It is important to highlight that depending on the method 
of computation (report or drug–event), the nij are not identical to those in Table 1. In Table 1, the nij correspond 
to the number of reports involving the drug–event combinations present in the database. The (%) sign before 
n2i denotes the number of reports containing product B but not product A. The (%) sign before n3i denotes the 
number of reports containing neither product A nor product B.
Reports containing the 
event (E) of interest
Reports not containing 
the event of interest
Total
Reports containing product A (regardless of 
any other co-suspected drug incl. product B)
n11 n12 n1.
Reports containing product B (masking) but 
not product A
(%)n21 (%)n22 (%)n2.
Reports containing neither product A nor 
product B
(%)n31 (%)n32 (%)n3.
Total n.1 n.2 n..
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We have used two sets of criteria to define SDRs, 
depending on whether we used the PRR or its 
lower interval limit: a number of three reports or 
above combined with either a threshold (>) of 2 
for the PRR or 1 for Lower95CI.14 A masking 
effect was defined by a value of MR or MRCI 




Substituting in the formula of the 95% confidence 
interval of the measures of disproportionality for 
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Table 3. Simulation aimed at assessing the effect of the respective allocation of reports containing both A and B to the products A 
and B, respectively. The nij represent the number of reports in the database. ROUND is the expression representing the rounding of 
the number to the nearest integer (natural number).
Event (E) of interest Other events Total
Product A n11
1; 3; 5; 10; 50; 100; 1000; 10,000
n1. – n11= n12
5; 10; 50; 100; 500; 1000; 5000; 10,000
n1.
Reports containing both A and B ROUND[%min(n11, n21)]
% = 0, 10%, 25%, 50%, 75% and 100%
ROUND[%min(n12, n22)]
% = 0, 10%, 25%, 50%, 75% and 100%
 
Product B (masking) n21
5; 10; 50; 100; 500; 1000; 10,000
n22
20; 50; 100; 250; 500; 1000; 5000; 10,000
%n2.
All other products in the database 
(excluding both A and B)
n31
100; 1000; 5000; 10,000
n32
2000; 10,000; 100,000; 1,000,000
n3.
Total n.1 n.. – n.1 = n.2 n..
Table 4. Mathematical expressions of the masking ratios for the three main measures of disproportionality (RRR, PRR, ROR) and 
their respective confidence intervals used on spontaneous reporting system databases. The corresponding definitions of the nij 
included in this table are given in Table 1 (the corresponding formulae for a computation at the report level can be obtained by using 
the corresponding values from Table 2).
Measure of 
disproportionality



















n n n n
= + − −
1 1 1 1





























1 1 1 1
1 1 1 1
11 1 1
11 1 1 21 2
. . . ..
. . .. .
n n n n





























1 1 1 1





























1 1 1 1
1 1 1 1
11 21 31 1 2 3
11 31 1 3
. . . .
. .
n n n n n n




























1 1 1 1



























1 1 1 1
1 1 1 1
11 12 21 31 22 32
11 12 31 32
.
n n n n n n








F Maignen, M Hauben et al.
journals.sagepub.com/home/taw 235
















where MD denotes the measure of disproportion-
ality used in the analysis for product A before 
removal (MD) or after removal (MD′) of masking 
product B and se is the standard error (MD can 
either be the RRR, PRR or ROR). Taking the 
logarithm of Equation 2 gives:
ln MRCI MR( ) = + −ln( ) . ( )1 96 se se′
where se and se′ denote the standard errors of the 
confidence interval before (se) or after (se′) the 
removal of masking product B.
The asymptotic standard error of the logarithm 
of the relative reporting ratio (RRRA) is given 
by:3,14,17
se
n n n n
≈ + − −
1 1 1 1
11 1 1. . ..
and the value of the approximate standard error of 
the logarithm of the RRRA(withoutB), after removal of 
masking product B (Table 1), is equal to:
se
n n n n n n
′( )
. . .. .





1 1 1 1
11 1 1 21 2
The exact MRCI of the lower bound of the 95% 
confidence interval for the RRRA given masking 
product B is therefore equal to:
ln( ) ln( ) [ . ]








n n n n n n
n
α 0 025
1 1 1 1
1
11 1 1 21 2
11
1 1 1


















where z[ . ]α 0 025⩽  (= –1.96) is the lower 95% 
point of the standard normal distribution. Table 4 
contains the expressions of the standard errors, 
MRs of the measures of disproportionality and their 
respective Lower95CI for the RRR, PRR and ROR.
Noting that n.. is generally very large in spontane-


































The study of the masking function associated 
with the use of the Lower95CI of the RRR pro-
vides some insight into the masking mechanisms 
associated with the use of the measures of dispro-
portionality and their respective confidence inter-
vals. The results are presented for the RRR; 
however, they remain valid for the other measures 
of disproportionality (it can easily be seen from 
the formulae in Table 4 and checked computa-
tionally that the values of the elements under the 
two square roots of the standard errors are simi-
lar, returning almost identical results across the 
different measures of disproportionality). If our 
assumptions concerning n.. and n2. are met, 
Equation 4 shows that MRCI varies from MR, 
when n21 is equal to zero (no masking effect), to 
infinity as n21 tends to n.1.
Assuming that n.., n1., n.1 are large (e.g. >100), an 
approximation of MRCI (for the RRR) can be 










































that is, MRCI=MR MF×  where MF is a multi-
plication factor by which MRCI can be obtained 
via the MR of the RRR. The study of this multipli-
cation factor provides an interesting insight on the 
properties of the MRCI compared with the MR.
This approximation of the MRCI shows that the 
percentage of reports (x) containing the masking 
product (n21) among the reports for the reaction 
of interest (n.1) dramatically influences the mag-
nitude of the masking associated with the confi-
dence interval. However, the number and the 
percentage of reports involving the product for 
Therapeutic Advances in Drug Safety 8(7)
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which the DA is conducted (n11) also play an 
important role in the shape of the resulting mask-
ing function of MRCI (Figure 1).
Unlike for the masking function associated with 
the RRR, which is hyperbolic regardless of the 
value of the ratio n21/n.1, the masking function 
(Equation 5) associated with the Lower95CI can 
take different shapes depending on the total num-
ber of reports for the reaction of interest (n.1) and 
the number of reports of that event involving the 
products of interest (A) (n11) among the total 
number of reports containing the reaction of 
interest (n.1) (Figures 1 and 2). When the per-
centage of reports involving product A in the total 
number of reports for the reaction of interest is 
<10% (i.e. when the contribution of the expres-
sion in the exponential part of the function 
becomes negligible), the masking function is 
hyperbolic, which provides two interesting fea-
tures: first, the masking has a ‘buffering zone’ (for 
values of x approximately included between 0.1 
and 0.7) in which the masking does not increase 
importantly as x increases (Figure 3). Second, 
and more importantly, the magnitude of the 
masking effect can be estimated with a simple 
hyperbolic function from the value of the ratio 
x = n21/n.1. Unfortunately, under other 
circumstances these two convenient properties 
are lost with the masking effect associated with 
the use of Lower95CI. This implies that simple 
rules proposed in previous studies that can be 
Figure 1. Shape of the masking function depending 
on the respective number and proportion of reports 
involving the product A of interest (n11) among all the 
products for the reaction of interest (n.1). The plot was 
computed for values of n11 of 5 reports and values of 
n.1 of 10 reports (i.e. n11 representing 50% of the total 
number of reports for the reaction of interest). x = 
n21/n.1 (from 0 to 0.5), y = n.2/n.. (from 0 to 0.95) and z 
is the value of MRCI.
Figure 2. Shape of the masking function (value of 
MRCI) depending on the respective number and 
proportion of reports involving the product A of 
interest (n11) among all the products for the reaction 
of interest (n.1). The plot was computed for values 
of n11 of 5 reports and values of n.1 of 50 reports [i.e. 
n11 representing 10% of the total number of reports 
for the event (E) of interest]. x = n21/n.1 (from 0 to 
0.95) and y = n.2/n.. (from 0 to 0.95) and z is the 
value of MRCI. The graph shows that under these 
circumstances the masking function is hyperbolic.
Figure 3. The graph is a cross-sectional view of 
the value of the masking ratio (y) as a function of 
the proportion of reports containing the masking 
product B (but not the product of interest A) among 
the total number of reports containing the event (E) of 
interest (n.1). The graph shows the buffering zone of 
a hyperbolic masking function. This zone is included 
between proportions of reports from 0.1 to 0.7. The 
value of MRCI increases dramatically when the 
proportion %n21/n.1 is above this value.
F Maignen, M Hauben et al.
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used to approximate the MR only provide a satis-
factory estimate of the MRCI when the multipli-
cation factor is close to 1. The multiplication 
factor only remains close to 1 when the number of 
reports involving the reaction of interest (n.1) is 
important (e.g. >100) and as long as the propor-
tion of reports involving the product of interest 
(n11) remains low compared to n.1 (e.g. <10% of 
the reports for the reaction of interest) (Table 5). 
This important finding implies that the properties 
of the approximate MR that we describe above 
can only be extended to the MRCI when these 
two conditions are met.
Equation 3 shows that the computation of the 
MRCI (like the exact MR) is also dramatically 
influenced by the method of computation (at the 
report or drug–event level).9 The MRCI is drug–
event specific for the RRR when the computa-
tion is performed at the drug–event level. 
Unfortunately, in the other situations (for the 
PRR and ROR and when the computation is per-
formed at the report level for the RRR), the 
MRCI remains strictly specific for both product 
A, the masking product B and the event (E) of 
interest. This implies that, like for the exact MR, 
an important number of computations will have 
to be performed to detect a possible masking 
effect associated with the use of the Lower95CI of 
the measures of disproportionality (the number of 
computations is a quadratic function of the num-
ber of drug–event pairs included in the data-
base).8,9 We could not find any way to bring down 
the number of computations associated with 
MRCI via a simplification of its computation.
Simulation
Our simulation originally yielded 905,091 SDRs 
with the PRR and 1,038,067 with its Lower95CI 
based on approximately two million simulated 
contingency tables. The removal of the masking 
resulted in a gain of 77,036 SDRs with the PRR 
(an additional 8.5% SDRs) and 68,900 SDRs 
with the Lower95CI (an additional 6.6% SDRs). 
The removal of any effect (masking or revealing 
effect) resulted in a net gain of approximately 5% 
new SDRs for both methods (Figures 4 and 5). 
We emphasize that under normal circumstances, 
the number of SDRs to be reviewed would be 
much lower. However, the percentages of addi-
tional SDRs unravelled by the unmasking are 
very similar to the number that we observed pre-
viously in real databases.8 Our simulation vali-
dated our mathematical algorithm as the MRCI 
exactly predicted the direction and the magnitude 
of the masking observed for the confidence inter-
val of the PRRA since the observed MRCI 
(Equation 1) and calculated MRCI (Equation 3) 
provided identical results.
A very close correlation between the masking 
effect associated with the PRR and the masking 
effect associated with its confidence interval 
established in our mathematical framework has 
been observed in our simulation (Figure 6). In 
particular, our simulation confirms that the 
masking product inducing the highest masking 
effect on a given drug–event pair for the PRR will 
also be the product inducing the highest masking 
effect for the confidence interval (Figures 6  
and 7).
Among the records that were not associated with 
an SDR using the PRR (1,159,293), 62.9% of 
these (728,735) were affected by a masking effect 
(MR strictly > 1) and 367,828 (31.7%) were 
involved in a masking effect greater than 1.1, sug-
gesting that most of the masking effect is of a 
moderate magnitude. Very similar figures were 
found using the Lower95CI. From the original 
records not originally highlighted as an SDR 
(1,026,317), 64.8% of these (665,473) were 
affected by a masking effect (MRCI > 1) but only 
32.9% of these (337,628) were affected by a 
moderate masking effect (MR > 1.1). The pres-
ence of a higher masking (defined by an arbitrary 
threshold of 1.5 for the MR) involved 21.6% of 
the (simulated) records not originally involved in 
an SDR for the PRR (250,778) and 22.6% of the 
records for the Lower95CI (232,022). Overall, 
the extent of important masking affecting the 
original non-SDRs remained low (Figure 8). The 
simulation showed that the proportion of new 
SDRs revealed by the unmasking and common to 
both methods increased with the value of the 
respective MRs. The number of new SDRs 
revealed after the removal of the masking effect 
common to both methods was 42,054 new SDRs 
(i.e. 55% of the new SDRs for the PRR and 61% 
of the new SDRs for the Lower95CI). This pro-
portion increased with the value of the MR to 
reach, respectively, 68% and 81% in the presence 
of important masking (value above 3 for both 
ratios) (Figure 9). These results show that the 
removal of masking of high magnitude tends to 
reveal identical SDRs across the two methods.
Discussion
Previous attempts have been made to propose an 
algorithm to assess and quantify the masking 
Therapeutic Advances in Drug Safety 8(7)
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Table 5. Computation of the masking ratio for the PRR and masking ratio for its confidence interval under the 
scenario that n2. and n3. are large (>100 reports) with n2./n3. = 0.005 and n1. = 100. The percentages represent 
the proportion of reports including the masking product B among the total number of reports involving the 
reaction of interest (n21/n.1). The table shows that the masking ratio (for the confidence interval) cannot be 
easily estimated since the multiplication factor differs from one when the number of reports for the reaction 
of interest (n.1) is <100 and x is high (above 50%). The cells in red highlight the computations for which MF < 
0.95. N/A denotes that the computation is not applicable.
n21/n.1 10% 25% 50% 75% 80%
n11 = 3 and n.1 = 20  
MR 1.13 1.41 2.42 8.46 16.92
MRCI 1.12 1.36 2.14 4.82 6.01
MF 0.99 0.96 0.88 0.57 0.36
n11 = 5  
MR 1.15 1.49 2.99 N/A N/A
MRCI 1.13 1.4 2.38 N/A N/A
MF 0.98 0.94 0.8 N/A N/A
n11 = 10  
MR 1.24 1.99 N/A N/A N/A
MRCI 1.18 1.63 N/A N/A N/A
MF 0.95 0.82 N/A N/A N/A
n11 = 3 and n.1 = 50  
MR 1.11 1.34 2.13 4.68 6.68
MRCI 1.11 1.32 2.05 4.14 5.55
MF 1 0.99 0.96 0.88 0.83
n11 = 5  
MR 1.12 1.36 2.24 5.6 8.96
MRCI 1.11 1.34 2.12 4.62 6.53
MF 0.99 0.99 0.95 0.83 0.73
n11 = 10  
MR 1.14 1.42 2.65 13.27 N/A
MRCI 1.13 1.38 2.38 7.3 N/A
MF 0.99 0.97 0.9 0.55 N/A
n21/n.1 10% 25% 50% 75% 80%
n11 = 3 and n.1 = 100  
MR 1.11 1.34 2.05 4.39 5.68
MRCI 1.11 1.33 2.01 4.15 5.25
MF 1 0.99 0.98 0.95 0.92
n11 = 5  
MR 1.11 1.35 2.1 4.73 6.3
MRCI 1.11 1.34 2.05 4.36 5.63
MF 1 0.99 0.98 0.92 0.89
n11 = 10  
MR 1.12 1.38 2.24 5.97 8.96
MRCI 1.12 1.36 2.15 5.15 7.17
MF 1 0.99 0.96 0.86 0.8
MF, multiplication factor; MR, masking ratio; MRCI, MR for the lower bound of the 95% confidence interval.
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Figure 4. Number of signals of disproportionate reporting (SDRs) identified in the simulation after removal 
of the masking effect for the PRR. The figure also breaks down the number of SDRs (in purple) and non-
SDRs (in green) that have been highlighted by each and both of the methods used in the study. The sectors in 
light colours indicate the percentage of records (non-SDRs in light green, SDRs in light purple) highlighted 
before and after removal of the masking. The sectors in dark colours indicate the percentage of new records 
highlighted after removal of the masking. Finally, the sectors that have been exploded from the pie chart 
correspond to the SDRs that have disappeared (exploded sector in green) and the new SDRs that have 
appeared (exploded sector in purple) common to both methods after removal of the masking effect.
Figure 5. Number of signals of disproportionate reporting (SDRs) identified in the simulation after removal of 
the masking effect for the Lower95CI. The figure also breaks down the number of SDRs (in purple) and non-
SDRs (in green) which have been highlighted by each and both of the methods used in the study. The sectors 
in light colours indicate the percentage of records (non-SDRs in light green, SDRs in light purple) highlighted 
before and after removal of the masking. The sectors in dark colours indicate the percentage of new records 
highlighted after removal of the masking. Finally, the sectors that have been exploded from the pie chart 
correspond to the SDRs that have disappeared (exploded sector in green) and the new SDRs that have 
appeared (exploded sector in purple) common to both methods after removal of the masking effect.
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effect associated with the use of measures of dis-
proportionality and their corresponding confi-
dence intervals.6 The MR for the confidence 
interval is a variable that provides a direct quanti-
fication of the direction (masking or promoting 
effect) and magnitude of the masking effect asso-
ciated with the use of Lower95CI. We have estab-
lished the existence of a direct association between 
the masking effect with the use of measures of 
disproportionality and their respective confidence 
intervals (Lower95CI). In particular for a given 
drug–event pair, in the presence of a masking 
effect (MRCI > 1.1), the product responsible for 
the highest masking effect with the MD will also 
be the product inducing the highest masking 
effect when the corresponding Lower95CI is 
used. However, considering the differences 
observed between the MR and MRCI and in the 
absence of comparison between the MRCI with 
approximations of MR, we recommend using our 
exact algorithm (and not our proposed approxi-
mation of the MR) to estimate the magnitude of 
the masking associated with the Lower95CI.
Our simulation suggests that the extent of mask-
ing on a given database is likely to be very similar 
across the two methods and also with other meas-
ures of disproportionality for which we have 
developed an algorithm (ROR, RRR). In addi-
tion, we have established that an important 
Figure 6. Relation between the masking ratio 
of the measure of disproportionality (PRR) and 
its confidence interval (lower bound of its 95% 
confidence interval) according to the value of n11 
(values of n11 from purple = 1, 3, 5, 10, 50, 100, 
1000 to blue = 10,000). The masking ratio of the 
confidence interval is influenced by the number 
of reports of the product (A) (n11) on which the 
disproportionality analysis is  
conducted (different colour lines). For an identical 
masking effect observed with the PRR, the masking 
ratio associated with the corresponding lower 
bound of the 95% confidence interval will decrease 
as the number of reports containing product A 
increases.
Figure 7. Relation (correlation) between the masking effect associated with the use of the masking ratio and 
its confidence interval. The plots are displayed according to the value of n31 (orange), n32 (green) and n11 (values 
of n11 from purple = 1, 3, 5, 10, 50, 100, 1000 to blue = 10,000). The axes of the plot on the right-hand side are 
on a logarithmic scale. These plots show that for a given drug–event pair, the product inducing the highest 
masking effect with the PRR will also induce the highest effect on the corresponding lower bound of the 95% 
confidence interval.
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proportion of identical drug–event associations 
affected by the presence of an important masking 
effect will be revealed by the unmasking exercise, 
whether the PRR or its Lower95CI is used. We 
have also observed some masking effects of very 
high magnitude (MR or MRCI ⩾ 3) that was due 
to the conduct of a simulated analysis, which cov-
ers extreme situations unlikely to be encountered 
in practice. The results of our simulation can be 
extrapolated to any database containing more 
than 2000 reports.
Simulations have been previously used to under-
stand masking mechanisms, but only covered a 
limited number of situations.10–12,15 In our pre-
vious studies, the results observed in our 
Figure 8. Extent of the masking effect associated with the use of the PRR (left-hand side) and with the 
Lower95CI (right-hand side) in the simulation performed in the study. The presence of important masking 
(defined as a masking ratio >3) was low and very similar across the two methods (data visualization available 
at the following URL: www-958.ibm.com/software/data/cognos/manyeyes/visualizations/new/bubble-chart/
number-of-records/1).
Figure 9. Number of new SDRs revealed according to the value of the respective masking ratios (MR and 
MRCI) before the removal of the masking effect. The proportion of new SDRs unmasked common to both 
methods increases with the magnitude of the masking effect originally affecting the record.
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simulations perfectly predicted the results 
observed on two large spontaneous databases.8,9 
It also allowed us to study the influence of dif-
ferent parameters on the masking effect in a 
controlled setting. It therefore provides an 
excellent working environment to test the algo-
rithm on situations mimicking databases of rad-
ically different sizes, which is difficult to perform 
in real life. On the other hand, we believe that 
the contingency tables generated by our simula-
tion cannot realistically simulate the presence 
and distribution of true effects or false-positives 
across the drug–event pairs; we did not assess 
the usefulness (gained or lost performance and 
more importantly its public health impact) on 
the detection of true effects of any unmasking 
exercise in such a controlled setting. This assess-
ment should be conducted on real spontaneous 
reporting databases (of different settings and 
different sizes).9
We have previously observed on two large spon-
taneous reporting system databases that the 
extent of masking associated with the PRR was 
low and mostly, but not only, affected events 
which were rarely reported (i.e. for which fewer 
than 100 reports were present in the databases). 
We have also observed that masking affected 
events involved in stimulated or over-reporting.7 
We have also demonstrated a major potential 
public health value of this exercise since one 
SDR revealed by our unmasking exercise later 
proved to be involved in a risk that led to the 
revocation of the marketing authorizations for 
fusafungine sprays in the EU (our DA was con-
ducted 5 years before the regulatory action). This 
signal was revealed despite a moderate masking 
effect (MR = 1.04).8,19
The use of Lower95CI is associated with some 
practical issues. First, no straightforward simplifi-
cation can be used to detect and assess the mag-
nitude of the masking affecting the reactions that 
are rarely reported, that is those that have fewer 
than 100 reports. In the absence of a simplified 
algorithm, we recommend the use of the exact 
MRCI. Second, like for the MR, we also show 
that the unmasking algorithm is dramatically 
affected by the method of computation – at the 
drug–event or report level – and is associated with 
an important amount of computations (the num-
ber of which is a quadratic function of the num-
ber of drug–event combinations present in the 
database). Unfortunately, unlike for the MR, we 
did not find any way to simplify our algorithm to 
bring down the number of computations. 
Considering that the mathematical expression of 
the MRCI is more complicated than that of the 
MR, simplifications require assumptions that can 
have an unpredictable effect on the MRCI.
The potential real-world public health benefits of 
removing the masking effect associated with the 
quantitative methods based on DA have been 
demonstrated in specific datasets but may be fur-
ther investigated to establish whether they are 
robust and generalizable to other datasets. As we 
demonstrated before, this beneficial effect is 
highly situation-dependent and is influenced by 
the size of the database, type of products included 
in the database, extent of simulated reporting, 
importance of reactions associated with a high 
probability of an association with a drug aetiol-
ogy, etc. One key issue for the future will be to 
prospectively assess the public health benefits of 
removing a masking effect in a database and iden-
tifying the situations in which the removal might 
be beneficial (either in terms of number of true 
effects identified or in terms of time gained by 
the unmasking). Two studies have shown that 
unmasking can reduce the time necessary to 
detect signals of important public health rele-
vance in specific datasets.7,8 Some previous retro-
spective studies have already reported a benefit 
by identifying true effects unravelled by the 
unmasking and by demonstrating that signals 
might be detected earlier.7,11,12,15,20 However, 
with our study, we provide strong evidence that 
the public health impact of the unmasking 
exercise that we have demonstrated with the 
measures of disproportionality will also probably 
be observed with the MRCI.
Revealing true effects is only one side of the 
coin. This study and previous studies conducted 
with the PRR suggest that the unmasking is 
likely to inflate the rate of false-positives identi-
fied by the quantitative methods (even more if 
the algorithm is run iteratively).6,9 The rate 
of true-/false-positive SDRs revealed by the 
unmasking has not been systematically studied 
or quantified particularly in a prospective way to 
minimize any hindsight bias. Such evaluation 
poses some practical and methodological chal-
lenges. In particular, it would be necessary to 
adjudicate the SDRs in a blinded way (without 
knowing whether the SDRs were present initially 
or after removal of the masking) to avoid any 
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assessment bias.21 In addition, considering that 
SRS databases can have significantly different 
features in terms of size, type of products 
covered and reports received and accepted, 
and subsequently entered (e.g. FAERS, VAERS, 
EudraVigilance, VigiBase, etc.),13,22 such evalu-
ation would also have to be repeated on different 
types of databases. The limited number of stud-
ies aimed at assessing the impact of the masking 
effect of disproportionality analyses have shown 
that reports including important events for phar-
macovigilance23 can be affected by a masking eff
ect.7,8,10–12,15 In that respect, our algorithm can 
be run on any database provided that appropri-
ate contingency tables are used for the DA and 
strict allocation rules of the reports containing 
both product A and masking product B are 
applied.
Finally, we highlight an important caveat of our 
results. Our unmasking algorithm can potentially 
be run ad libitum to fulfil pre-specified expecta-
tions. We suggest that any unmasking should pri-
marily be directed by the number of true-positives 
or rate of true-positive/false-positive findings con-
firmed by a clinical evaluation6,14,20 unravelled by 
the removal of the masking product(s) inducing 
the masking of highest magnitude. No threshold 
to define the presence of consequential masking 
can be recommended at this stage.
Conclusion
We highlight a direct relation between the mask-
ing observed with the PRR and for its confidence 
interval. The detection and quantification of the 
masking effect of measures of disproportionality 
and their confidence intervals can be automated. 
At the moment, the real benefits of this unmask-
ing in terms of new true-positive signals (rate 
of true-positive/false-positive) or time gained in 
revealing of signals using this method are not yet 
definitively established. These benefits should be 
demonstrated in the context of prospective stud-
ies aimed at assessing the performances of signal 
detection in real conditions. The implementation 
of this algorithm will require some additional 
resources (computational and human), in partic-
ular on large spontaneous reporting system data-
bases in which masking is difficult to identify 
empirically.
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